Clinical Trials Logo

Polyneuropathies clinical trials

View clinical trials related to Polyneuropathies.

Filter by:

NCT ID: NCT02260388 Completed - Clinical trials for Cryptogenic Sensory Polyneuropathy

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

PAIN-CONTRoLS
Start date: October 2014
Phase: Phase 4
Study type: Interventional

The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and mexiletine in treating cryptogenic sensory polyneuropathy (CSPN).

NCT ID: NCT02191826 Completed - Clinical trials for Familial Amyloid Polyneuropathy (FAP)

Study of SOM0226 in Familial Amyloid Polyneuropathy

Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Clinical proof of concept study to evaluate SOM0226 efficacy in TTR Amyloidosis.

NCT ID: NCT02175004 Completed - Amyloidosis Clinical Trials

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Start date: June 26, 2014
Phase: Phase 3
Study type: Interventional

This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.

NCT ID: NCT02129231 Completed - Oxidative Stress Clinical Trials

Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy

Start date: February 2012
Phase: Phase 2
Study type: Interventional

Aims: To evaluate the effect of ezetimibe/simvastatin and rosuvastatin on oxidative stress and mitochondrial function in patients with DPN. Methods: We performed a randomized, double-blinded, placebo-controlled phase II clinical trial in adult patients with type 2 Diabetes Mellitus (T2DM) who had Diabetic Polyneuropathy (DPN) evaluated by composite scores and nerve conduction studies (NCS), HBA1C <12% (108 mmol/mol), previous exclusion of other neuropathies. Ninety-eight persons with T2DM were allocated 1:1:1 to either placebo, ezetimibe/simvastatin 10/20 mg or rosuvastatin 20 mg for 16 weeks, and healthy controls (not randomized) were included for comparisons. Primary outcomes were lipid peroxidation (LPO), nitric oxide (NO), and total antioxidant capacity (TAC); secondary were clinical, NCS and metabolic parameters. Results were expressed as mean ± standard deviation (SD) or standard error of the mean (SEM), frequencies and percentages. Non-parametric analysis was used.

NCT ID: NCT02124616 Recruiting - Clinical trials for Spinal Muscular Atrophy

National Registry for Egyptian Pediatric Neuromuscular Diseases

Start date: April 2014
Phase: N/A
Study type: Observational [Patient Registry]

Our aim is to establish multi-center national Egyptian database of information for inherited and acquired neuromuscular diseases in infants and children from 0 to 18 years of age.

NCT ID: NCT02121678 Completed - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy

Effect of Resistance and Aerobic Exercise in CIDP or MMN

Start date: April 2014
Phase: N/A
Study type: Interventional

Resistance and aerobic exercise has been shown to be effective for maintenance of muscle strength in patients with neuromuscular diseases. Exercise in CIDP and MMN is sparsely described. The aim of the study is to evaluate changes in muscle strength during high intensive resistance training and changes in maximal oxygen consumption (VO2-max) during high intensive aerobic training in patients with CIDP or MMN in maintenance therapy with subcutaneous immunoglobulin. The hypotheses are that muscle strength and VO2-max are significantly increased during the training sessions.

NCT ID: NCT02111590 Completed - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy

Immunoglobulin Dosage and Administration Form in CIDP and MMN

Start date: January 2014
Phase: N/A
Study type: Observational

The aim of this study is to evaluate development of hemolysis and the variation in isokinetic muscle strength in two groups of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN) 1. Patients shifted from 3- or 6-weekly treatment with intravenous immunoglobulin (IVIG) to weekly treatment with subcutanoeus immunoglobulin (SCIG) 2. Patients shifted from SCIG treatment with Subcuvia® or Hizentra® to Gammanorm®. Hypotheses - During treatment with IVIG blood hemoglobin will fluctuate with a decline due to infusion, whereas it will remain stable during SCIG treatment without fluctuation - Isokinetic muscle strength in affected muscle groups is more stable during treatment with SCIG than with IVIG - Blood hemoglobin and changes in muscle strength is comparable during Subcuvia® or Hizentra® and Gammanorm® treatment

NCT ID: NCT02107469 Completed - Clinical trials for Diabetic Neuropathies

A Study of Phyllanthus Niruri and Sida Cordifolia in Diabetic Peripheral Polyneuropathy

VEDICINE
Start date: June 2014
Phase: N/A
Study type: Interventional

The purpose of the study is to determine whether phyllanthus niruri and sida cordifolia are effective in treatment of diabetic polyneuropathy compared to placebo. Also two different administration forms (extract capsules and crude herbs) are used to find out whether there are differences in efficiency and compliance.

NCT ID: NCT02104921 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Innovative Ultrasound Technology in Neuromuscular Disease

AQUIRe
Start date: December 1, 2013
Phase:
Study type: Observational

This study is utilizing ultrasound measurement to measure neuromuscular disease status in adult patients. The hypothesis is the by quantifying ultrasound data, it is possible that ultrasound can be utilized as a tool to determine if a disease is responding to therapy or progressing.

NCT ID: NCT02061059 Not yet recruiting - Diabetes Mellitus Clinical Trials

Cost-effectiveness of In-shoe Pressure Measurement for Therapeutic Shoes

Start date: March 2014
Phase: N/A
Study type: Interventional

The purpose of this study is determine whether the use of plantar pressure measurements in the production of customized therapeutic footwear for patients with diabetes and a history of foot ulceration results in lower production costs and more pressure relief, compared to the standard production. A secondary objective is to explore if a difference in durability can be observed in pressure reduction and development of (pre-) ulcerative lesions between the shoes produced with and without plantar pressure measurements.